keyword
MENU ▼
Read by QxMD icon Read
search

Stratified medicine in cancer

keyword
https://www.readbyqxmd.com/read/29228059/does-access-to-clinical-study-reports-from-the-european-medicines-agency-reduce-reporting-biases-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials-on-the-effect-of-erythropoiesis-stimulating-agents-in-cancer-patients
#1
Eliane Rohner, Michael Grabik, Thomy Tonia, Peter Jüni, Frank Pétavy, Francesco Pignatti, Julia Bohlius
Since 2010, the European Medicines Agency (EMA) has provided access to clinical study reports (CSRs). We requested CSRs for randomized controlled trials (RCTs) of erythropoiesis-stimulating agents (ESAs) in cancer patients from EMA and identified RCT publications with literature searches. We assessed CSR availability and completeness, the impact of unreported and unpublished data obtained from CSRs on the effects of ESAs on quality of life (QoL) of cancer patients, and discrepancies between data reported in the public domain and in CSRs...
2017: PloS One
https://www.readbyqxmd.com/read/29224672/sle-redefined-on-the-basis-of-molecular-pathways
#2
REVIEW
Guillermo Barturen, Marta E Alarcón-Riquelme
The implementation of precision medicine requires the recruiting of patients in statistically enough numbers, the possibility of obtaining enough materials, and the integration of data from various platforms, which are all real limitations. These types of studies have been performed extensively in cancer but barely on systemic lupus erythematosus (SLE) or other rheumatic diseases. To consider the practical use of the information obtained from such studies, we have to take into account the best biological fluid to use, the ease to perform the analysis in clinical practice, and its relevance to clinical practice...
June 2017: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/29174310/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii-iiia-n1-n2-egfr-mutant-nsclc-adjuvant-ctong1104-a-randomised-open-label-phase-3-study
#3
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Ke Fei, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Hong-Hong Yan, Xue-Ning Yang, Qing Zhou, Yi-Long Wu
BACKGROUND: Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II-IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data suggest patients with EGFR-mutant stage IB-IIIA resected NSCLC could benefit from adjuvant EGFR tyrosine kinase inhibitor treatment. We aimed to compare the efficacy of adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected EGFR-mutant stage II-IIIA (N1-N2) NSCLC. METHODS: We did a randomised, open-label, phase 3 trial at 27 centres in China...
November 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29170406/an-extracellular-matrix-related-prognostic-and-predictive-indicator-for-early-stage-non-small-cell-lung-cancer
#4
Su Bin Lim, Swee Jin Tan, Wan-Teck Lim, Chwee Teck Lim
The prognosis and prediction of adjuvant chemotherapy (ACT) response in early-stage non-small cell lung cancer (NSCLC) patients remain poor in this era of personalized medicine. We hypothesize that extracellular matrix (ECM)-associated components could be potential markers for better diagnosis and prognosis due to their differential expression in 1,943 primary NSCLC tumors as compared to 303 normal lung tissues. Here we develop a 29-gene ECM-related prognostic and predictive indicator (EPPI). We validate a robust performance of the EPPI risk scoring system in multiple independent data sets, comprising a total of 2,071 early-stage NSCLC tumors...
November 23, 2017: Nature Communications
https://www.readbyqxmd.com/read/29154898/evaluation-of-dynamic-contrast-enhanced-mri-biomarkers-for-stratified-cancer-medicine-how-do-permeability-and-perfusion-vary-between-human-tumours
#5
Ross A Little, Hervé Barjat, Jennifer I Hare, Mary Jenner, Yvonne Watson, Susan Cheung, Katherine Holliday, Weijuan Zhang, James P B O'Connor, Simon T Barry, Sanyogitta Puri, Geoffrey J M Parker, John C Waterton
BACKGROUND: Solid tumours exhibit enhanced vessel permeability and fenestrated endothelium to varying degree, but it is unknown how this varies in patients between and within tumour types. Dynamic contrast-enhanced (DCE) MRI provides a measure of perfusion and permeability, the transfer constant K(trans), which could be employed for such comparisons in patients. AIM: To test the hypothesis that different tumour types exhibit systematically different K(trans). MATERIALS AND METHODS: DCE-MRI data were retrieved from 342 solid tumours in 230 patients...
November 14, 2017: Magnetic Resonance Imaging
https://www.readbyqxmd.com/read/29140483/integrative-whole-person-oncology-care-in-the-uk
#6
Catherine Zollman, Axel Walther, Helen E Seers, Rachel C Jolliffe, Marie J Polley
The term "whole-person cancer care"-an approach that addresses the needs of the person as well as treating the disease-is more widely understood in the United Kingdom than its synonym "integrative oncology." The National Health Service (NHS) provides free access to care for all, which makes it harder to prioritize NHS funding of whole-person medicine, where interventions may be multimodal and lacking in cost-effectiveness data. Despite this, around 30% of cancer patients are known to use some form of complementary or alternative medicine (CAM)...
November 1, 2017: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/29097403/gridss-sensitive-and-specific-genomic-rearrangement-detection-using-positional-de-bruijn-graph-assembly
#7
Daniel L Cameron, Jan Schröder, Jocelyn Sietsma Penington, Hongdo Do, Ramyar Molania, Alexander Dobrovic, Terence P Speed, Anthony T Papenfuss
The identification of genomic rearrangements with high sensitivity and specificity using massively parallel sequencing remains a major challenge, particularly in precision medicine and cancer research. Here, we describe a new method for detecting rearrangements, GRIDSS (Genome Rearrangement IDentification Software Suite). GRIDSS is a multithreaded structural variant (SV) caller that performs efficient genome-wide break-end assembly prior to variant calling using a novel positional de Bruijn graph-based assembler...
November 2, 2017: Genome Research
https://www.readbyqxmd.com/read/29069872/potential-therapeutic-targets-of-triple-negative-breast-cancer-based-on-its-intrinsic-subtype
#8
REVIEW
Fangyuan Shao, Heng Sun, Chu-Xia Deng
Triple-negative breast cancer (TNBC) is an aggressive subgroup of human breast cancer, which is characterized as estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (HER2) negative. TNBC is the most difficult breast cancer subgroup to treat, due to its unresponsiveness to current clinical targeted therapies, high rate of recurrence, and poor prognosis. Thus, there is an urgent medical need to identify therapeutic targets and develop more effective stratified medicine for the treatment of TNBC...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29068364/advances-in-precision-medicine-tailoring-individualized-therapies
#9
Kyle B Matchett, Niamh Lynam-Lennon, R William Watson, James A L Brown
The traditional bench-to-bedside pipeline involves using model systems and patient samples to provide insights into pathways deregulated in cancer. This discovery reveals new biomarkers and therapeutic targets, ultimately stratifying patients and informing cohort-based treatment options. Precision medicine (molecular profiling of individual tumors combined with established clinical-pathological parameters) reveals, in real-time, individual patient's diagnostic and prognostic risk profile, informing tailored and tumor-specific treatment plans...
October 25, 2017: Cancers
https://www.readbyqxmd.com/read/29063873/future-role-of-endoscopic-ultrasound-in-personalized-management-of-pancreatic-cancer
#10
REVIEW
Marie Ooi, An Phan, Nam Q Nguyen
Pancreatic ductal adenocarcinoma (PDAC) is aggressive and lethal with the majority of cases presenting with advanced unresectable disease due to delayed diagnosis. Despite improvement in surgery, chemotherapies, and intensive care medicine, the outcome of PDAC remains poor, which may relate to the tumor biology. Recent data suggest that PDAC is a "systemic cancer" with complex molecular or genomics derangement with marked heterogeneity. The ability to characterize the PDAC better by detailed evaluation of tissue biomarkers or genomics allows for improved prediction of prognosis and stratification of treatment, a concept known as "personalized cancer therapy...
September 2017: Endoscopic Ultrasound
https://www.readbyqxmd.com/read/29061215/-relationship-between-mta1-expression-and-prognosis-of-chinese-lung-cancer-%C3%A2-patients-a-meta-analysis
#11
Hai Zhong, Yun Tang, Ying Wang, Wei Gu
BACKGROUND: It has been proven that metastasis associated protein 1 (MTA1) was correlated with tumor invasion and migration and poor prognosis of several malignant carcinomas. The prognostic role of MTA1 expression in lung cancer remained controversial, we performed this meta-analysis to assess the prognostic value of MTA1 expression in lung cancer. METHODS: A systematic literature search was conducted to identify eligible studies which dealing with the relationship between MTA1 expression and prognosis of lung cancer in PubMed, Embase, Wanfang databases, China Biology Medicine disc and China National Knowledge Infrastructure...
October 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29019032/nanotechnology-as-a-delivery-tool-for-precision-cancer-therapies
#12
Bhawna Sharma, Rachael M Crist, Pavan P Adiseshaiah
Genomic analyses from patients with cancer have improved the understanding of the genetic elements that drive the disease, provided new targets for treating this relentless disease, and offered criteria for stratifying patient populations that will benefit most from treatments. In the last decade, several new targeted therapies have been approved by the FDA based on these omics findings, leading to significantly improved survival and quality of life for select patient populations. However, many of these precision medicines, e...
November 2017: AAPS Journal
https://www.readbyqxmd.com/read/28980936/null-genotype-of-gstt1-may-be-associated-with-esophageal-cancer-risk-a-meta-analysis-in-chinese-individuals
#13
Y-P Liu, L Li
Many studies have analyzed the association between between GSTT1 polymorphism and esophageal cancer, however, the results remained inconclusive. We therefore performed an updated meta-analysis based on Chinese individuals. PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure and Chinese Biology Medicine were searched up to December 2016. An OR with the corresponding 95% CI was used to assess the strength of the association. This meta-analysis included 12 studieswith 1246 cases and 1863 controls...
September 30, 2017: Cellular and Molecular Biology
https://www.readbyqxmd.com/read/28947138/speeding-towards-individualized-treatment-for-pancreatic-cancer-by-taking-an-alternative-road
#14
REVIEW
Juan Iovanna, Nelson Dusetti
Accumulation of genetic mutations drives the development of pancreatic ductal adenocarcinoma (PDAC). Contrary to what it is expected, however, genetic analyses, no matter how precise or detailed, do not allow the identification of patient groups with different clinical outcomes or the selection of specific treatments. In fact, clinical outcome and sensitivity to treatments are associated with a given phenotype and are therefore associated at a transcriptomic level. In practical terms, therefore, the most appropriate readout for phenotypically stratifying PDACs should be transcriptomic and not genetic analysis...
December 1, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28942131/effect-of-early-use-of-chinese-herbal-products-on-mortality-rate-in-patients-with-lung-cancer
#15
Hsuan-Shu Shen, Shu-Hui Wen
ETHNOPHARMACOLOGICAL RELEVANCE: Patients with lung cancer are frequently treated with Western medical treatments. Recently, patients have begun to use Chinese medicine to strengthen the immune system and alleviate side effects. AIM OF THE STUDY: We aimed to evaluate the association between mortality rate and early use of Chinese herbal products (CHPs) among patients with lung cancer. MATERIALS AND METHODS: We conducted a retrospective cohort study based on the National Health Insurance Research Database, Taiwan Cancer Registry, and Cause of Death Data...
September 20, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28933670/on-enrichment-strategies-for-biomarker-stratified-clinical-trials
#16
Xiaofei Wang, Jingzhu Zhou, Ting Wang, Stephen L George
In the era of precision medicine, drugs are increasingly developed to target subgroups of patients with certain biomarkers. In large all-comer trials using a biomarker stratified design, the cost of treating and following patients for clinical outcomes may be prohibitive. With a fixed number of randomized patients, the efficiency of testing certain treatments parameters, including the treatment effect among biomarker-positive patients and the interaction between treatment and biomarker, can be improved by increasing the proportion of biomarker positives on study, especially when the prevalence rate of biomarker positives is low in the underlying patient population...
September 21, 2017: Journal of Biopharmaceutical Statistics
https://www.readbyqxmd.com/read/28919861/lactobacillus-rhamnosus-gg-an-overview-to-explore-the-rationale-of-its-use-in-cancer
#17
REVIEW
Giuseppe L Banna, Francesco Torino, Francesco Marletta, Maria Santagati, Rossella Salemi, Elisa Cannarozzo, Luca Falzone, Francesco Ferraù, Massimo Libra
Cancer is the second leading cause of death in the western world. In the era of precision medicine, a significant number of cancer patients can be cured with several anti-cancer therapeutic regimens. However, therapy failure may be caused by treatment side effects, such as diarrhea, especially occurring in patients with gastrointestinal or pelvic malignancies. In particular, diarrhea is one of the most frequent gastrointestinal toxicity during cancer treatment and it can result from nearly bot chemo- and radio-therapeutic strategies currently used...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28917544/effects-on-the-incidence-of-cardiovascular-events-of-the-addition-of-pioglitazone-versus-sulfonylureas-in-patients-with-type-2-diabetes-inadequately-controlled-with-metformin-tosca-it-a-randomised-multicentre-trial
#18
Olga Vaccaro, Maria Masulli, Antonio Nicolucci, Enzo Bonora, Stefano Del Prato, Aldo P Maggioni, Angela A Rivellese, Sebastiano Squatrito, Carlo B Giorda, Giorgio Sesti, Paolo Mocarelli, Giuseppe Lucisano, Michele Sacco, Stefano Signorini, Fabrizio Cappellini, Gabriele Perriello, Anna Carla Babini, Annunziata Lapolla, Giovanna Gregori, Carla Giordano, Laura Corsi, Raffaella Buzzetti, Gennaro Clemente, Graziano Di Cianni, Rossella Iannarelli, Renzo Cordera, Olga La Macchia, Chiara Zamboni, Cristiana Scaranna, Massimo Boemi, Ciro Iovine, Davide Lauro, Sergio Leotta, Elisabetta Dall'Aglio, Emanuela Cannarsa, Laura Tonutti, Giuseppe Pugliese, Antonio C Bossi, Roberto Anichini, Francesco Dotta, Antonino Di Benedetto, Giuseppe Citro, Daniela Antenucci, Lucia Ricci, Francesco Giorgino, Costanza Santini, Agostino Gnasso, Salvatore De Cosmo, Donatella Zavaroni, Monica Vedovato, Agostino Consoli, Maria Calabrese, Paolo di Bartolo, Paolo Fornengo, Gabriele Riccardi
BACKGROUND: The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. METHODS: TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50-75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2-3 g per day) were recruited from 57 diabetes clinics in Italy...
September 12, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28840558/the-power-of-zebrafish-in-personalised-medicine
#19
Sarah Baxendale, Freek van Eeden, Robert Wilkinson
The goal of personalised medicine is to develop tailor-made therapies for patients in whom currently available therapeutics fail. This approach requires correlating individual patient genotype data to specific disease phenotype data and using these stratified data sets to identify bespoke therapeutics. Applications for personalised medicine include common complex diseases which may have multiple targets, as well as rare monogenic disorders, for which the target may be unknown. In both cases, whole genome sequence analysis (WGS) is discovering large numbers of disease associated mutations in new candidate genes and potential modifier genes...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28772289/association-of-mismatch-repair-mutation-with-age-at-cancer-onset-in-lynch-syndrome-implications-for-stratified-surveillance-strategies
#20
Neil A J Ryan, Julie Morris, Kate Green, Fiona Lalloo, Emma R Woodward, James Hill, Emma J Crosbie, D Gareth Evans
Importance: Lynch syndrome is caused by dominantly inherited germline mutations that predispose individuals to colorectal, endometrial, ovarian, and other cancers through inactivation of the cellular mismatch repair system. Lynch syndrome-associated cancers are amenable to surveillance strategies that may improve survival. The age at which surveillance should start is disputed. Objective: To determine whether mutated gene and type of mutation influence age at onset of Lynch syndrome-associated cancers...
August 3, 2017: JAMA Oncology
keyword
keyword
100257
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"